The Gary Null Show - 10.31.22

Videos: Member of The FDA Vax Panel Said “We Are Killing More People Than We Are Saving With The Shots” RFK : The Real Anthony Fauci Clip (1st clip 5:50 – 2nd Clip 4:37) Dr Shoemaker – C19 vaxx – lethal short and long term 10/22/22 (13:00) Clare Daly Latest Top 7 Contributions in the EU. (Start @ 4:32) Neil Oliver: We are expected to forget those promising to fix the disaster caused it (10:28) MASSIVE GLACIER MELTDOWN THREATENS CIVILIZATION | Countdown to Armageddon (7:42) Chlorophyllin shows promise for inflammatory bowel disease Sichuan University (China) & Cedars Sinai Medical Center, October 28 2022.  The August 2022 issue of the American Journal of Physiology Gastrointestinal and Liver Physiology reported research which found that supplementation with chlorophyllin suppressed intestinal inflammation in a mouse model of inflammatory bowel disease (IBD).  Chlorophyllin is a water-soluble derivative of chlorophyll, the pigment that gives green plants their color. “Consuming green-colored vegetables or green pigment supplement such as chlorophyllin might help people with inflammatory bowel disease,” senior author Xiaofeng Zheng, PhD, of Sichuan University West China Hospital in Chengdu, China predicted.  Current treatments for inflammatory bowel diseases include immunosuppressant medications and surgery, both of which are associated with potentially serious adverse effects. “The study was designed to determine the effect of safe agents that are easily available to have a beneficial effect in inflammatory bowel disease,” commented report coauthor Stephen J. Pandol, MD, of Cedars Sinai Medical Center in Los Angeles. The team induced colitis in mice by administering dextran sulfate sodium. They found that supplementing the animals’ diets with chlorophyllin or directly administering the compound suppressed intestinal inflammation and downregulated disease-associated autophagy in the intestine.  “What we found in the study was that the agent used, chlorophyllin, would inhibit the inflammation and tissue damage that occurs in an experimental model of colitis,” Dr Pandol commented. “In this case it was in a mouse model. The results were promising in an experimental model, and those can justify a clinical trial.” Curcumin Prodrug Shows Promise As Cancer Treatment Without Toxic Side Effects Kyoto University (Japan), October 30, 2022 Curcumin, the biologically active compound found in turmeric, has shown lots of promise in clinical cancer research. A new study from Kyoto University adds more evidence that supports its use in clinical-care settings. Researchers are developing a curcumin prodrug called TBP1901 that demonstrates anti-tumor effects without adverse toxicities. Curcumin is an appealing compound for oncology researchers, as many current pharmacological treatments lead to significant side effects in patients. Thus far, anecdotal findings report strong efficacy when taken orally among cancer patients. However, until this recent development, curcumin’s low bioavailability and instability has put limitations on its clinical use. Kanai and team have maneuvered their way around this by successfully identifying the enzyme GUSB, which may activate curcumin to increase its bioavailability. The enzyme plays a crucial role in TBP1901 conversion to curcumin. However, the research team hypothesized that the conversion wouldn’t be observable in mice with genetically-weakened GUSB enzyme. Further, they were able to confirm through analysis with CRISPR-Cas9 screening that curcumin may also have additional specific therapeutic targets. “The high conversion rate of TBP1901 to curcumin in bone marrow warrants its clinical application for diseases growing in the marrow like multiple myeloma and leukemia,” states Kanai. Now that scientists have begun to crack the code with curcumin, the cancer field may start to put things into motion as more targets and enzymatic processes are explained.  Study Reveals How Turmeric Inhibits Pancreati